(FBT) NYSE Arca Biotechnology - Overview
Etf: Biotech, Equal-Weighted, U.S., Mid/Large-Cap
| Risk 5d forecast | |
|---|---|
| Volatility | 21.9% |
| Relative Tail Risk | -0.46% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.64 |
| Alpha | 3.28 |
| Character TTM | |
|---|---|
| Beta | 0.805 |
| Beta Downside | 0.695 |
| Drawdowns 3y | |
|---|---|
| Max DD | 20.05% |
| CAGR/Max DD | 0.52 |
Description: FBT NYSE Arca Biotechnology January 19, 2026
The First Trust NYSE Arca Biotechnology Index Fund (FBT) commits at least 90% of its net assets-including any investment borrowings-to the securities that compose its underlying index, which is an equal-dollar weighted basket of the 30 largest biotechnology firms. This concentration strategy aims to track the index’s performance closely while maintaining a diversified exposure across the sector.
Key metrics to watch: the fund’s expense ratio sits at roughly 0.55%, positioning it competitively among biotech ETFs; its 12-month total return has hovered around 8% (as of the latest quarter), reflecting the sector’s mixed pipeline outcomes. Primary drivers of future performance include FDA approval cycles, R&D intensity (measured by biotech R&D spend as a % of revenue, currently averaging 18% across the index constituents), and macro-level factors such as interest-rate trends that affect financing for high-cash-burn companies.
For a deeper dive into valuation and risk analytics, consider exploring ValueRay’s platform to complement your research.
What is the price of FBT shares?
Over the past week, the price has changed by -0.17%, over one month by -0.87%, over three months by +8.97% and over the past year by +18.06%.
Is FBT a buy, sell or hold?
What are the forecasts/targets for the FBT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 225.7 | 6.2% |
FBT Fundamental Data Overview February 04, 2026
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 2.38b USD (2.38b + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
EV/FCF = unknown (FCF TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 2.38b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 2.38b / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 8.88% (E(2.38b)/V(2.38b) * Re(8.88%) + (debt-free company))
Discount Rate = 8.88% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow 0.0)